The HIV-associated tuberculosis epidemic--when will we act? (Q37757652)

22 August 2017

1 reference

title

The HIV-associated tuberculosis epidemic--when will we act? (English)

1 reference

22 August 2017

0 references

0 references

1 reference

Brian G Williams

9

0 references

Elizabeth L. Corbett

object named as

Elizabeth L Corbett

3

0 references

Dermot Maher

object named as

Dermot Maher

8

0 references

Stephen Lawn

4

object named as

Stephen D Lawn

1 reference

22 August 2017

2

Rony Zachariah

1 reference

22 August 2017

1

Anthony D Harries

1 reference

22 August 2017

6

Rhehab Chimzizi

1 reference

22 August 2017

10

Kevin M De Cock

1 reference

22 August 2017

Ezio T Santos-Filho

5

1 reference

PubMed ID

20488516

22 August 2017

Mark Harrington

7

1 reference

PubMed ID

20488516

22 August 2017

language of work or name

English

0 references

publication date

18 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

375

1 reference

22 August 2017

1906-1919

1 reference

22 August 2017

9729

1 reference

Who has access to counseling and testing and anti-retroviral therapy in Malawi - an equity analysis

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

The fight against stigma: an overview of stigma-reduction strategies and interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Tuberculosis control in the era of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Can antiretroviral therapy eliminate HIV transmission?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

An algorithm for tuberculosis screening and diagnosis in people with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Confronting the scientific obstacles to global control of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Nursing and community rates of Mycobacterium tuberculosis infection among students in Harare, Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Epidemiology of HIV-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Natural ventilation for the prevention of airborne contagion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

The infectiousness of tuberculosis patients coinfected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Treatment of latent tuberculosis infection in HIV infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Childhood tuberculosis - global epidemiology and the impact of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

HIV prevention for a threatened continent: implementing positive prevention in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Treatment outcomes of patients with HIV and tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Timing of initiation of antiretroviral drugs during tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a panacea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

How can the community contribute in the fight against HIV/AIDS and tuberculosis? An example from a rural district in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Health systems exist for real people. Introduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

The 'diagonal' approach to Global Fund financing: a cure for the broader malaise of health systems?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Improving microscope quality is a good investment for under-resourced laboratories

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Patient retention and attrition on antiretroviral treatment at district level in rural Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Rapid expansion of the health workforce in response to the HIV epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Integrating tuberculosis and HIV care in the primary care setting in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Assessing the quality of data aggregated by antiretroviral treatment clinics in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

An assessment of interactions between global health initiatives and country health systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Venice statement: global health initiatives and health systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Effect of early versus deferred antiretroviral therapy for HIV on survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960409-6

1 reference

7 January 2021

10.1016/S0140-6736(10)60409-6

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20488516